#399 ‒ The evolution of Alzheimer's disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D.

July 12, 2026

AI Summary

5 min read

Dr. Gayatri Devi, a neurologist and psychiatrist specializing in memory disorders, joins Peter Attia to discuss a rapidly changing landscape in dementia care. The core of her approach is a rejection of the one-size-fits-all, inevitable-decline model of Alzheimer’s disease. Instead, she treats dementia as a highly heterogeneous spectrum, where early detection, personalized multimodal treatment, and careful risk stratification can meaningfully alter a patient’s trajectory—sometimes even leading to stabilization or improvement.

Dementia as a Spectrum, Not a Binary

Devi emphasizes that dementia is an umbrella term for progressive loss of brain connectivity and function, with Alzheimer’s disease being the most common type. However, she argues that Alzheimer’s itself is not a monolithic condition. It presents variably depending on the individual’s brain reserve, the specific brain regions affected, and the presence of comorbid pathologies like vascular disease or Lewy body disease. “There really is a spectrum aspect to Alzheimer's and dementia, which people don't recognize,” she says. “Much like autism, it really can span the spectrum from very mild impairment that doesn't get worse to severe impairment that kind of deteriorates rapidly.”

Continue reading the full summary in the app — free to try.

Read Full Summary →

Free • No credit card required

Listen to Audio Summary Open in App

Never miss an episode of The Peter Attia Drive

Get every new episode summarized in your inbox — free, ~5 minutes to read.

No spam. Unsubscribe anytime.

What you'll learn

1 (03:52) **A personalized approach to dementia** - Dr. Devi describes the biggest shifts in her understanding: dementia as a spectrum disorder and the advent of personalized, multimodal treatment.
2 (07:17) **Alzheimer’s is not a binary disease** - Dr. Devi explains the spectrum of Alzheimer’s, its subtypes, and the challenge of diagnosing high-functioning individuals.
3 (11:46) **The order of events in Alzheimer’s pathology** - The discussion moves to what starts the disease process, from inflammation to amyloid to tau.
4 (13:37) **Neuroinflammation as a new frontier** - Dr. Devi highlights the role of viral infections and immune modulation in Alzheimer’s risk.
5 (17:31) **How Dr. Devi evaluates a patient** - A detailed walkthrough of her rigorous, multi-day diagnostic workup for high-functioning patients.
6 (22:03) **The role of lumbar puncture vs. blood biomarkers** - Dr. Devi shares her cautious view on current blood-based tests for Alzheimer’s.
7 (24:16) **Piecing together the diagnosis and creating a treatment plan** - How she integrates test results to determine pathology, velocity, and treatment aggressiveness.

+ Full timestamped outline available in the app

Guests on this episode

Peter Attia

Show Notes

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

Gayatri Devi is a nationally recognized neurologist specializing in memory disorders, including Alzheimer's disease and related dementias. In this episode, Gayatri explains how to think about dementia as a spectrum—including Alzheimer's disease, vascular dementia, Lewy body dementia, and mixed presentations—while exploring the evolving biology of amyloid, tau, and neuroinflammation and why brain pathology does not always correlate with symptoms. She discusses her approach to detecting subtle cognitive decline in high-functioning individuals, the role of biomarkers and APOE4 testing in asymptomatic patients, the benefits and risks of anti-amyloid therapies such as lecanemab and donanemab, and strategies for minimizing treatment-related complications. Gayatri also examines why some patients may stabilize or even improve with individualized care, the overlap among different dementia syndromes, and the relationship between menopause, estrogen, and cognition—including her concept of menopause-related cognitive impairment. Finally, she discusses how advances in early detection, AI-assisted monitoring, targeted therapies, and precision medicine are reshaping the future of dementia care.

We discuss:

Gayatri's training and clinical focus, why dementia is a spectrum disease, and how personalized treatment is changing Alzheimer's care [3:45];
How Alzheimer's disease fits within the broader spectrum of dementia: diagnosis, biomarkers, and early pathophysiology [7:15];
The emerging role of neuroinflammation and viral infections in Alzheimer's disease [13:30];
Gayatri's comprehensive approach to evaluating cognitive decline in high-functioning patients [17:45];
Why forgetting names is usually normal and when word-finding problems become concerning [29:00];
Why women are at higher risk for Alzheimer's disease and how menopause influences cognition [33:45];
The promise and limitations of blood-based biomarkers for diagnosing Alzheimer's disease [40:15];
When preclinical Alzheimer's screening is appropriate and how to interpret positive biomarker results [45:00];
Case study: early Alzheimer's prevention in a highly-functional woman in her 50s with two copies of APOE4 [47:15];
A